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Using the Comprehensive Complication Index to Assess the
Impact of Neoadjuvant Chemoradiotherapy on Complication
Severity After Esophagectomy for Cancer
Nina Nederlof, MD1, Annelijn E. Slaman, BSc3, Pieter van Hagen, MD1, Ate van der Gaast, MD, PhD2,
Ksenija Slankamenac, MD, PhD4, Suzanne S. Gisbertz, MD, PhD3, Jan J. B. van Lanschot, MD, PhD1,
Bas P. L. Wijnhoven, MD, PhD1, Mark I. van Berge Henegouwen, MD, PhD3, and CROSS-Study Group
1Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Department of Radiation
Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands; 3Department of Surgery G4-115, Academic
Medical Center, Amsterdam, The Netherlands; 4University Hospital Zurich, Zurich, Switzerland
ABSTRACT
Background. Neoadjuvant chemoradiotherapy (nCRT)
followed by surgery for patients with esophageal or junc-
tional cancer has become a standard of care. The
comprehensive complication index (CCI) has recently been
developed and accounts for all postoperative complica-
tions. Hence, CCI better reflects the burden of all combined
postoperative complications in surgical patients than the
Clavien–Dindo score alone, which incorporates only the
most severe complication. This study was designed to
evaluate the severity of complications in patients treated
with nCRT followed by esophagectomy versus in patients
who underwent esophagectomy alone using the compre-
hensive complication index.
Study-design. All patients included in the CROSS trial—a
randomized, clinical trial on the value of nCRT followed
by esophagectomy—were included. Complications were
assessed and graded using the Clavien–Dindo classifica-
tion. CCI was derived from these scores, using the CCI
calculator available online (www.assessurgery.com). CCI
of patients who underwent nCRT followed by surgery was
compared with the CCI of patients who underwent surgery
alone.
Results. In both groups 161 patients were included. The
median (and interquartile range) CCI of patients with
nCRT and surgery was 26.22 (17.28–42.43) versus 25.74
(8.66–43.01) in patients who underwent surgery alone
(p = 0.58). There also was no difference in CCI between
subgroups of patients with anastomotic leakage, pulmonary
complications, cardiac complications, thromboembolic
events, chyle leakage, and wound infections.
Conclusions. Neoadjuvant chemoradiotherapy according
to CROSS did not have a negative impact on postoperative
complication severity expressed by CCI compared with
patients who underwent surgery alone for potentially cur-
able esophageal or junctional cancer.
Esophageal cancer remains one of the most common
cancers worldwide.1 Treatment for patients with potentially
curable esophageal cancer is an esophagectomy with gas-
tric tube reconstruction. Meta-analyses of randomized,
controlled trials comparing neoadjuvant chemoradiother-
apy plus surgery to surgery alone showed that
multimodality treatment improves overall survival, but
side-effects (e.g., radiofibrosis, suppressed immune func-
tion, impaired nutritional and hematological status) could
increase morbidity and mortality after esophagectomy.2–17
The largest, published, randomized clinical trial on the
value of neoadjuvant chemoradiotherapy (CROSS-trial)
also showed a survival benefit.8 Importantly, there was no
difference in the frequency of complications and
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postoperative mortality between the patients who were
treated with neoadjuvant chemoradiotherapy followed by
surgery and the patients who underwent surgery alone.
In the past decades, not only the frequency but also the
severity of postoperative complications has become an
important quality measure in surgical studies. Also,
patients’ reported grading of complications gives a better
insight into the burden of a complicated postoperative
course. Therefore, several severity-scoring systems have
been developed.18–22 A novel and validated scoring system
is the Comprehensive Complication Index (CCI).20,23 CCI
summarizes the frequency, severity, and patient’s rating of
complications by using the adopted ‘‘operating risk index’’
in a single score that ranges between 0 (no complication)
and 100 (death) based on the established Clavien–Dindo
classification.22 Therefore, it accounts for the whole burden
of all complications. A recent study showed that CCI is a
sensitive method that is superior to traditional endpoints,
because it summarizes the whole burden of postoperative
complications to the patient with respect to complica-
tions.20 Whereas traditional endpoints showed no
significant differences for incidence of postoperative
complications within the CROSS trial, the current study
was designed to evaluate the overall effect of neoadjuvant
chemoradiotherapy on the severity of postoperative com-
plications and the overall burden in patients of the CROSS
trial. Therefore, the CCI was compared between patients
with esophageal or esophagogastric junction cancer who
underwent chemoradiotherapy plus surgery versus patients
who underwent surgery alone.
PATIENTS AND METHODS
Patients with esophageal cancer or cancer of the
esophagogastric junction (cT1-4aN0-3M0) who underwent
a curative surgical resection of the esophagus and who
participated in the CROSS trial were selected from the
study database. The CROSS trial is a multicenter, ran-
domized, controlled trial that compared overall survival for
patients who were treated with neoadjuvant chemoradio-
therapy followed by esophagectomy and the patients who
underwent esophagectomy alone. The inclusion and
exclusion criteria as well as staging procedures have been
described previously.24 As the study focuses on compli-
cation severity after esophagectomy, patients who did not
undergo resection were removed from the study cohort.
Complications
Complications were defined using the complete and
commonly applicable National Cancer Institute’s Common
Terminology Criteria for Adverse Events, 4.0.25 Because
these criteria do not provide a definition of anastomotic
leakage, the definition according to Bruce et al.26 was used:
drainage of saliva or gastrointestinal content from the
surgical join between the oesophagus and gastric tube. The
luminal contents may emerge externally or internally or
may be collected near the anastomosis with or without
systemic complications. Only complications within
30 days after the operation and/or during hospital stay were
assessed.
CCI
The CCI is a complication index introduced by
Slankamenac et al.23 in 2013 and is based on the Clavien–
Dindo classification22 (Appendix). In the development of
the CCI, data on common postoperative complications
were gathered and rated by both patients and physicians.
By this method, each complication is validated and given a
fixed number and also includes patient’s perspective about
the severity. After this, a score is calculated for each grade
in the Clavien–Dindo classification. To calculate the CCI,
all complications that a patient develops after surgery are
summarized and computed through the operation risk index
approach (commonly used in economics). This can be done
easily and free of charges at www.assessurgery.com. The
final index yields a score from 0 (no complication) to 100
(death).27
To investigate whether postoperative complication
severity is influenced by neoadjuvant treatment, the
severity of all combined complications was measured using
the CCI. Based on results in earlier studies of patients who
underwent esophageal cancer surgery in which specific
complications have shown an increase in incidence, six
subgroups were formed in this study. For example, some
studies show influence of neoadjuvant treatment on pul-
monary complications, due to the radiation field. In
subgroup 2, patients with pulmonary complications are
compared. Only patients with the specific complication
were used to calculate the specific complication CCI.
Grading of Complications
We used the original database of the CROSS study in
which postoperative complications were scored by data
managers in each participating center. Cross checking of
these complications and grading every complication
according to the Clavien–Dindo classification was done by
one of the authors (NN). The CCI was calculated after-
wards. In addition, for each patient the traditional
endpoints, the total number of complications, the presence
of any complication (yes/no) and the most severe compli-
cations (CIIIb according to the Clavien–Dindo
classification) were assessed.
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Treatment
As previously described,24 patients randomized to
neoadjuvant chemoradiotherapy underwent five weekly
cycles of chemoradiotherapy (carboplatin/paclitaxel with
41.1 Gy concurrent radiotherapy) followed by surgery,
preferably within 4–6 weeks of completion. Patients ran-
domized to the surgery alone arm underwent
esophagectomy as soon as possible.
Statistical Analysis
Adjustment for possible confounders was not necessary,
because the data were controlled for confounding by ran-
domization. Baseline continuous data were described as
means with standard deviation or, in case of a not-normally
distributed variable, with the median and interquartile
range. Normal distribution was calculated using the Kol-
mogorov–Smirnov test. Groups were compared using the
nonparametric Mann–Whitney U test. For cross-
tabulations, Pearson’s chi-square test with continuity cor-
rection was used. All statistical analyses were performed
on the statistical package SPSS 22.0 (SPSS Inc., Chicago,
IL). p\ 0.05 two-sided was considered statistically
significant.
RESULTS
Of the 368 patients randomized in the CROSS trial, 322
patients were included in the present study.8 An overview
of inclusion and exclusion of patients in the present study is
shown in Fig. 1. Patient’s characteristics, including age,
sex, comorbidity, and surgical approach, were similar
between both groups (Table 1). More R0 resections were
performed in patients who received nCRT before
esophagectomy (p\ 0.001). In patients who were analyzed
in the current study (n = 322), the combined treatment
group 136 (85 %) patients developed at least one compli-
cation versus 125 (78 %) the surgery alone group
(p = 0.13; Table 2).
Grade I complications were seen in 43 % of patients
after neoadjuvant chemoradiotherapy plus surgery versus
49 % of patients after surgery alone (p = 0.37). There also
was no statistically significant difference for grade II-grade
V complications (Table 2).
Analyses in six subgroups showed that respiratory
complications, i.e., pneumonia were the most common (30
vs. 21 %, p = 0.32), followed by anastomotic leakage (23
vs. 30 %, p = 0.13) and cardiac arrhythmias (20 vs. 12 %,
p = 0.29). Significantly more infections of the chest
wound were found in patients with neoadjuvant treatment
who underwent a transthoracic esophagectomy (0 vs. 6 %,
p = 0.007). The incidence of all other complications was
not significantly different between the two groups.
There was no statistically significant difference in the
CCI between both groups. Median CCI in the combined
treatment group was 26.22 (IQR 17.28–42.43) compared
with 25.74 (IQR 8.66–43.01) in the surgery alone group
(p = 0.58; Table 3).
In subgroup analyses of the specific complications, CCI
for patients who underwent neoadjuvant chemoradiother-
apy and developed an anastomotic leak was not statistically
different from patients who underwent surgery alone: 8.66
[8.66–33.73] vs. 8.66 [8.66–33.73] (p = 0.78). The same
was true for the other subgroups with patients who devel-
oped pulmonary or cardiac complications, thromboembolic
event, chyle leakage, or wound infection (Table 3).
DISCUSSION
The Dutch CROSS study showed an absolute 5-years
survival benefit of 13 % for patients who underwent
neoadjuvant chemoradiotherapy followed by an
Randomization in 



















FIG. 1 Flowchart patients
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esophagectomy for esophageal or esophagogastric cancer.
Hence, neoadjuvant chemoradiotherapy is nowadays
widely used in clinical practice. However, it is important to
consider the possible harm of neoadjuvant chemoradio-
therapy, because trials frequently focus on the benefit of a
treatment.28–30 This may be caused by a lack of sensitive
outcome parameters, by underreporting, and by the strict
inclusion criteria of trials that are frequently broadened
after closure of the trial and the specifics of positive results.
Also, sample sizes often are rather small, masking the
incidence of selectively rare but potentially serious com-
plications. This study used the novel outcome measure for
postoperative complicated course (CCI) to compare the
additive impact of neoadjuvant chemoradiotherapy on the
severity of complications in patients after esophagectomy,
as the incidence of complications is already reported in the
CROSS study. Our results show neither a significant dif-
ference in CCI between both groups nor in the incidence of
specific common complications.
The benefit of neoadjuvant treatment has been a topic of
many studies but the harm has been described less exten-
sively. The Cochrane review, published in 2010,
demonstrates that postoperative complications often are ill
described or missing at all.7,31 Therefore, in their meta-
analysis no overall complication rate could be calculated.
In a retrospective study published by Morita et al. con-
taining 686 patients, the total number of complications, as
well as pulmonary complications and anastomotic leakage
developed more frequently in patients with neoadjuvant
treatment in comparison with patients without neoadjuvant
treatment.32 Bosch et al. confirmed an increase in car-
diopulmonary complications in the neoadjuvant treatment
group (pneumonia and cardiac arrhythmias).16 Merrit et al.,
in a retrospective cohort study of 138 patients, showed no
increase in postoperative morbidity and mortality but
concluded that major postoperative complications are
rather due to surgical technique and preoperative morbidity
rather than neoadjuvant therapy.10 Furthermore, Kelley
TABLE 1 Patient and tumor characteristics
nCRT and surgery (161) Surgery alone (161) p value
Age (year) median [range] 60 [37–76] 60 [36–76] 0.72
Sex (M:F) 129:34 123:38 0.41
WHO performance statusa
0 27 20 0.28
1 134 140 0.34
Comorbidity
Cardiovascular 45 (28 %) 40 (25 %) 0.48
Respiratory 17 (11 %) 19 (12 %) 0.69
Diabetes mellitus 14 (9 %) 11 (7 %) 0.55
Histology
Squamous cell carcinoma 37 37 1.0
Adenocarcinoma 121 120 1.0
Undifferentiated carcinoma 3 4 1.0
Tumor site
Proximal esophagus 2 (1 %) 3 (2 %) 1.0
Mid esophagus 24 (15 %) 16 (10 %) 0.23
Distal esophagus 112 (70 %) 123 (76 %) 0.20
Gastroesophageal junction 23 (14 %) 17 (12 %) 0.40
Mortality
30-day 3 (2 %) 4 (3 %) 1.00
In-hospital 5 (3 %) 6 (4 %) 0.99
Surgical approach
Transhiatal esophagectomy 72 (45 %) 72 (45 %) 1.0
Transthoracic esophagectomy 89 (55 %) 87 (54 %) 0.91
Resection with tumour-free margins p(R0) 148 (92 %) 111 (69 %) \0.001
Percentages may not add up to 100 because of rounding
WHO World Health Organization; nCRT neoadjuvant chemoradiotherapy
a WHO performance status scores are on a scale of 0–5, with lower numbers indicating better performance status; 0 indicates fully active, and 1
unable to carry out heavy physical work
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TABLE 2 Frequencies of Clavien–Dindo grades and postoperative complications in patients of the current study
nCRT and surgery (n = 161) Surgery alone (n = 161) p value
Any complication 136 (85 %) 125 (78 %) 0.13
Grade I complication 70 (43 %) 79 (49 %) 0.37
Grade II complication 90 (56 %) 85 (53 %) 0.65
Grade IIIa complication 58 (36 %) 52 (32 %) 0.56
Grade IIIb complication 25 (13 %) 28 (15 %) 0.76
Grade IVa complication 28 (15 %) 33 (20 %) 0.57
Grade IVb complication 3 (2 %) 6 (3 %) 0.50
Grade V complication 5 (3 %) 6 (3 %) 1.00
Subgroup 1: Anastomotic leakagea 37 (23 %) 49 (30 %) 0.16
Subgroup 2: Pulmonary complicationsb 81 (50 %) 82 (50 %) 1.00
Subgroup 3: Cardiac complicationsc 34 (21 %) 23 (14 %) 0.57
Subgroup 4: Thromboembolic events 6 (3 %) 4 (2 %) 1.00
Subgroup 5: Chyle leakaged 16 (10 %) 11 (7 %) 0.41
Subgroup 6: Wound infections 18 (11 %) 21 (13 %) 0.60
Anastomotic leakage 37 (23 %) 49 (30 %) 0.16
Leakage requiring surgical intervention 8 (4 %) 6 (3 %) 0.59
Pneumonia 49 (30 %) 40 (21 %) 0.32
Atelectasis 17 (11 %) 22 (14 %) 0.49
Empyema 14 (9 %) 25 (16 %) 0.09
Pneumothorax 10 (6 %) 14 (9 %) 0.52
Respiratory insufficiency 29 (15 %) 33 (20 %) 0.67
Reintubation 33 (20 %) 33 (20 %) 1.00
Thromboembolism 6 (3 %) 4 (2 %) 0.75
Cardiac arrhythmia 30 (20 %) 22 (12 %) 0.29
Myocardial infaction 0 (0 %) 1 (1 %) 1.00
Cardiac decompensation 4 (2 %) 0 (0 %) 0.13
Mediastinitis 6 (3 %) 11 (7 %) 0.32
Chylothorax 16 (10 %) 11 (7 %) 0.41
Vocal cord palsy 19 (12 %) 12 (7 %) 0.66
Wound infection neck 9 (6 %) 6 (3 %) 0.60
Wound infection thorax 0 (0 %) 9 (6 %) 0.007
Wound infection abdomen 9 (6 %) 6 (3 %) 0.60
Renal failure 4 (2 %) 1 (1 %) 0.37
Sepsis 7 (4 %) 10 (6 %) 0.62
Multi-organ failure 0 (0 %) 4 (2 %) 0.13
Readmittance ICU 30 (19 %) 27 (17 %) 0.66
Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0
nCRTS neoadjuvant chemoradiotherapy
a Anastomotic leakage was defined as: drainage of saliva or gastrointestinal content from the surgical join between the oesophagus and gastric
tube. The luminal contents may emerge externally or internally, or may be collected near the anastomosis with or without systemic complications
b Pulmonary complications were pneumonia (isolation of pathogen from sputum culture and a new or progressive infiltrate on chest radiograph),
serious atelectasis (lobar collapse on chest radiograph), pneumothorax (collection of air between the visceral and parietal pleural surfaces,
requiring drainage), pleural effusion (collection of fluid between the visceral and parietal pleural surfaces, requiring drainage), pulmonary
embolus (embolus detected on spiral CT or a ventilation–perfusion mismatch on a lung scintigram), and acute respiratory failure (partial pressure
of arterial oxygen\60 mm Hg while breathing ambient air)
c Cardiac complications were arrhythmia (any change in rhythm on the electrocardiogram, requiring treatment), myocardial infarction (two or
three of the following: previous myocardial infarction, electrocardiographic changes suggesting myocardial infarction, or enzyme changes
suggesting myocardial infarction), cardiac decompensation and left ventricular failure (marked pulmonary edema on a chest radiograph)
d Chylothorax was recorded when elevated levels of triglycerides in intrathoracic fluid [ 1 mmol l-1 (89 mg per deciliter)] were found.
Mediastinitis was scored when reported by the local investigator
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et al. performed a prospective trial in 2004, which showed
no significantly higher complication rate in patients with
preoperative chemoradiotherapy.13 In a study of 40 patients
by Bagheri et al., respiratory complications were closely
analyzed, and although there was a significant correlation
between the number of microorganisms in the sputum and
difficulty in weaning, there was no correlation found
between neoadjuvant treatment and pulmonary complica-
tions.15 Several meta-analyses showed a decrease in
mortality without any proof of a decrease in postoperative
complications, but most trials failed to produce information
about postoperative complications.4,6,9,17 Greer et al. found
no difference in their meta-analysis and concluded that
there was a need for large, randomized trials.5
With the recently developed sensitive comprehensive
complication index, it is possible to take the severity of all
complications into consideration, thus improving the
accuracy of reporting the impact of all side effects com-
bined.20,23 The CCI has been validated already in different
surgical trials, showing its value. The CCI incorporates
patients’ opinion on a complication, as well as the physi-
cians’ opinion. It also takes into account low-grade
complications, which are normally not considered an
endpoint but adds up to the patients’ postoperative expe-
rience. Additionally, the CCI can be used to compare the
severity of a specific complication (i.e., anastomotic leak-
age) between different patient groups (Table 3).
There are several limitations to the current study.
Because our study included patients from seven partici-
pating hospitals, it may be possible that there is some
difference in reporting and treatment of complications. All
complications were reviewed by one of the authors to
preserve uniformity in application of the Clavien–Dindo
classification. In the Netherlands, the transference to the
Medium or Intensive Care Unit for more intensive moni-
toring of the patients is relatively low, which in the
Clavien–Dindo system directly results in a grade IV com-
plication but is not always accompanied by organ failure.
The difference in complications scored in the CROSS trial
differ because of the difference between the Clavien–
Dindo classification and the CCI. In the CROSS study, only
the most severe complication counted. This study only
reports early complications, within 30 days and/or within
hospital admission. Later complications, e.g., stenosis or
complications due to recurrence, were not included.
Another possible limitation of this study is that postoper-
ative complications were not the primary endpoint of the
CROSS trial. The study was powered to show a difference
in overall survival; therefore, the sample size of this study
might be too small to show differences in rare complica-
tions. However, as described by Slankamenac et al., when
using the CCI as opposed to the original Clavien–Dindo
classification as an endpoint, meaningful comparison can
be obtained with smaller sample sizes.20
TABLE 3 Comprehensive complication Index computed for the whole study group as well as subgroups of common postoperative
complications
CRTx and surgery Surgery alone p value
CCI (whole group; N = 322) 26.22 (17.28–42.43) 25.73 (8.66–43.01) 0.58
CCI patients with anastomotic leakage (N = 86)a 8.66 (8.66–33.73) 8.66 (8.66–33.73) 0.78
CCI patients with pulmonary complications (N = 163)b 20.92 (20.92–42.43) 20.92 (20.92–42.43) 0.59
CCI patients with cardiac complications (N = 57)c 20.92 (20.92–20.92) 20.92 (20.92–20.92) 0.64
CCI patients with thromboembolic events (N = 10)d 20.92 (20.92–20.92) 20.92 (20.92–20.92) 1.0
CCI patients with chyle leak (N = 27)e 8.66 (8.66–20.92) 14.79 (8.66–31.85) 0.65
CCI patients with wound infections (N = 39)f 8.66 (8.66–8.66) 8.66 (8.66–8.66) 0.93
CCI for the whole group was computed on all patients. CCI of subgroups were calculated only in patients with the specific complication, to
compare the severeness of the specific complications between groups
Values are shown as median with interquartile range and p value
a Anastomotic leakage was defined as: drainage of saliva or gastrointestinal content from the surgical join between the oesophagus and gastric
tube. The luminal contents may emerge externally or internally, or may be collected near the anastomosis with or without systemic complications
b Pulmonary complications were pneumonia (isolation of pathogen from sputum culture and a new or progressive infiltrate on chest radiograph),
serious atelectasis (lobar collapse on chest radiograph), pleural effusion (collection of fluid between the visceral and parietal pleural surfaces,
requiring drainage) and acute respiratory failure (partial pressure of arterial oxygen\60 mm Hg while breathing ambient air)
c Cardiac complications were arrhythmia (any change in rhythm on the electrocardiogram, requiring treatment), myocardial infarction (two or
three of the following: previous myocardial infarction, electrocardiographic changes suggesting myocardial infarction, or enzyme changes
suggesting myocardial infarction), cardiac decompensation and left ventricular failure (marked pulmonary edema on a chest radiograph)
d Thromboembolic events were defined as a deep venous thrombosis (shown on echo) or pulmonary embolus (embolus detected on spiral CT or
a ventilation–perfusion mismatch on a lung scintigram)
e Chylothorax was recorded when elevated levels of triglycerides in intrathoracic fluid [ 1 mmol l-1 [89 mg dl-1)] were found
f Wound infections were defined as redness, inflammation, with extravasation of pus after drainage
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The CCI can be used as a tool to monitor postoperative
recovery in a detailed and structured way. Because all data in
the present study were prospectively registered, this study
shows a realistic view of postoperative complications in
patients with cancer of the esophageal and esophagogastric
junction. This study shows that the frequency of complications
described in patients extracted from CROSS trial is similar in
the two groups; and the outcome of specific complications in
the two groups is similar. Neoadjuvant chemoradiotherapy
does not show a negative impact on the overall postoperative
morbidity as expressed by the CCI compared with patients
who underwent surgery alone for potentially curable esopha-
geal or esophagogastric junctional cancer.
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